Table 3 Summary of study characteristics and subject matter
From: Statistical analyses of ordinal outcomes in randomised controlled trials: a scoping review
|  | Studies―n (%) |
|---|---|
Number of publications | 144 |
Year of publication―n (%) |  |
- 2017 | 23 (16%) |
- 2018 | 24 (17%) |
- 2019 | 21 (15%) |
- 2020 | 30 (21%) |
- 2021 | 30 (21%) |
- 2022 | 16 (11%) |
Funding source/s―n (%)a |  |
- Public | 104 (72%) |
- Industry | 57 (40%) |
- Non-profit | 39 (27%) |
Journal―n (%) |  |
- NEJM | 61 (42%) |
- JAMA | 40 (28%) |
- The Lancet | 34 (24%) |
- BMJ | 9 (6%) |
Medical condition studied - n (%) | Â |
- Stroke | 39 (28%) |
- COVID-19 | 22 (16%) |
- Atopic dermatitis | 6 (4%) |
- Cardiac arrest | 5 (3%) |
- Other | 73 (51%) |
Medical specialty studied―n (%) |  |
- Neurology | 54 (38%) |
- Infectious diseases | 22 (16%) |
- Dermatology | 13 (9%) |
- Psychiatry | 12 (9%) |
- Cardiology | 7 (5%) |
- Rheumatology | 7 (5%) |
- Other | 26 (18%) |
Clinical setting―n (%) | 141 (98%) |
Adaptive design used ―n (%)‡ | 58 (40%) |
Participants in analysis―median (IQR, range)b | 380 (202–803, 21–11016) |